Current and Future PET Imaging for Multiple Myeloma
Abstract
:1. Introduction
2. Myeloma Mouse Models
2.1. Human MM Xenograft Model
2.2. Mineral Oil-Induced Plasmacytoma 315 (MOPC315).BM Mouse Model
2.3. Spontaneous MM Mouse Model
2.4. Genetically Engineered Vk*Myc Mouse Model
Category | Myeloma Model | Origin | Transplanted Cells | Injection | MM Cell Growth | Reconstruction of Immune System | Bone Disease | References |
---|---|---|---|---|---|---|---|---|
Xenograft | SCID | Human MM cell lines | Subcutaneous | Subcutaneous | No | No | [22,23] | |
NOD/SCID | ||||||||
NOG | Subcutaneous Intravenous | Subcutaneous Bone marrow (intravenous) | No (subcutaneous) Yes (intravenous) | |||||
NSG | ||||||||
SCID-hu | Primary MM cells derived from patients with MM | Implanted bone | Within implanted bone | ? | Yes (implanted bone) | [25,26,27,28] | ||
SCID-rab | ||||||||
MIS(KI)TRG6 (GM-CSF/SIRPα/IL-3/IL-6 knock-in) | Primary MM cells derived from patients with MGUS/MM | Intrafemoral injection | Bone marrow | Yes (bone marrow) | ? | [29] | ||
Syngeneic | MOPC315.BM | BALB/c | MOPC315.BM | Intravenous | Bone marrow Spleen | Yes | Yes | [32] |
5TMM derived model | C57BL/KaLwRiJ | 5T2MM | Intravenous | Bone marrow Spleen | Yes | Yes | [34,35,36,37,38,39,40] | |
5T33MM | No | |||||||
5TGM1 | Yes | |||||||
Vk*Myc derived model | C57BL/6 | Vk12598 Vk12653 | Intravenous | Bone marrow Spleen | Yes | Yes | [41,42] |
3. Positron Emission Tomography (PET)
3.1. 18F-Fluorodeoxyglucose-PET
3.2. New PET Radiotracer
3.2.1. Peptide-Based Radiotracer
3.2.2. Antibody-Based Radiotracers
Radiotracers Targeting CD38 Receptor Expression for Imaging MM Cells
Radionuclides in Radiotracers for Immuno-PET of MM
Radiotracers Targeting Immune Cells for Imaging the Immune Microenvironment
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Rajkumar, S.V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am. J. Hematol. 2022, 97, 1086–1107. [Google Scholar] [CrossRef]
- Ho, M.; Patel, A.; Goh, C.Y.; Moscvin, M.; Zhang, L.; Bianchi, G. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia 2020, 34, 3111–3125. [Google Scholar] [CrossRef] [PubMed]
- Dutta, A.K.; Fink, J.L.; Grady, J.P.; Morgan, G.J.; Mullighan, C.G.; To, L.B.; Hewett, D.R.; Zannettino, A.C.W. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia 2019, 33, 457–468. [Google Scholar] [CrossRef] [PubMed]
- Palumbo, A.; Anderson, K. Multiple myeloma. N. Engl. J. Med. 2011, 364, 1046–1060. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morgan, G.J.; Walker, B.A.; Davies, F.E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 2012, 12, 335–348. [Google Scholar] [CrossRef]
- Zavidij, O.; Haradhvala, N.J.; Mouhieddine, T.H.; Sklavenitis-Pistofidis, R.; Cai, S.; Reidy, M.; Rahmat, M.; Flaifel, A.; Ferland, B.; Su, N.K.; et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer 2020, 1, 493–506. [Google Scholar] [CrossRef]
- Bailur, J.K.; McCachren, S.S.; Doxie, D.B.; Shrestha, M.; Pendleton, K.; Nooka, A.K.; Neparidze, N.; Parker, T.L.; Bar, N.; Kaufman, J.L.; et al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight 2019, 5, e127807. [Google Scholar] [CrossRef]
- García-Ortiz, A.; Rodríguez-García, Y.; Encinas, J.; Maroto-Martín, E.; Castellano, E.; Teixidó, J.; Martínez-López, J. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers 2021, 13, 217. [Google Scholar] [CrossRef] [PubMed]
- Mimura, N.; Hideshima, T.; Anderson, K.C. Novel therapeutic strategies for multiple myeloma. Exp. Hematol. 2015, 43, 732–741. [Google Scholar] [CrossRef] [Green Version]
- Touzeau, C.; Moreau, P.; Dumontet, C. Monoclonal antibody therapy in multiple myeloma. Leukemia 2017, 31, 1039–1047. [Google Scholar] [CrossRef]
- Dima, D.; Jiang, D.; Singh, D.J.; Hasipek, M.; Shah, H.S.; Ullah, F.; Khouri, J.; Maciejewski, J.P.; Jha, B.K. Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers 2022, 14, 4082. [Google Scholar] [CrossRef]
- Gulla, A.; Anderson, K.C. Multiple myeloma: The (r)evolution of current therapy and a glance into future. Haematologica 2020, 105, 2358–2367. [Google Scholar] [CrossRef] [PubMed]
- Durie, B.G.; Harousseau, J.L.; Miguel, J.S.; Bladé, J.; Barlogie, B.; Anderson, K.; Gertz, M.; Dimopoulos, M.; Westin, J.; Sonneveld, P.; et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20, 1467–1473. [Google Scholar] [CrossRef] [Green Version]
- Paiva, B.; van Dongen, J.J.; Orfao, A. New criteria for response assessment: Role of minimal residual disease in multiple myeloma. Blood 2015, 125, 3059–3068. [Google Scholar] [CrossRef] [Green Version]
- Kostopoulos, I.V.; Ntanasis-Stathopoulos, I.; Gavriatopoulou, M.; Tsitsilonis, O.E.; Terpos, E. Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Front. Oncol. 2020, 10, 860. [Google Scholar] [CrossRef]
- Cavo, M.; San-Miguel, J.; Usmani, S.Z.; Weisel, K.; Dimopoulos, M.A.; Avet-Loiseau, H.; Paiva, B.; Bahlis, N.J.; Plesner, T.; Hungria, V.; et al. Prognostic value of minimal residual disease negativity in myeloma: Combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood 2022, 139, 835–844. [Google Scholar] [CrossRef] [PubMed]
- Munshi, N.C.; Avet-Loiseau, H.; Anderson, K.C.; Neri, P.; Paiva, B.; Samur, M.; Dimopoulos, M.; Kulakova, M.; Lam, A.; Hashim, M.; et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020, 4, 5988–5999. [Google Scholar] [CrossRef]
- Landgren, O.; Devlin, S.; Boulad, M.; Mailankody, S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: A meta-analysis. Bone Marrow Transplant. 2016, 51, 1565–1568. [Google Scholar] [CrossRef] [Green Version]
- Avet-Loiseau, H.; Ludwig, H.; Landgren, O.; Paiva, B.; Morris, C.; Yang, H.; Zhou, K.; Ro, S.; Mateos, M.V. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. Clin. Lymphoma Myeloma Leuk. 2020, 20, e30–e37. [Google Scholar] [CrossRef] [PubMed]
- Kumar, S.; Paiva, B.; Anderson, K.C.; Durie, B.; Landgren, O.; Moreau, P.; Munshi, N.; Lonial, S.; Bladé, J.; Mateos, M.V.; et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet. Oncol. 2016, 17, e328–e346. [Google Scholar] [CrossRef]
- Hillner, B.E.; Siegel, B.A.; Shields, A.F.; Liu, D.; Gareen, I.F.; Hunt, E.; Coleman, R.E. Relationship between cancer type and impact of PET and PET/CT on intended management: Findings of the national oncologic PET registry. J. Nucl. Med. 2008, 49, 1928–1935. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mehdi, S.H.; Nafees, S.; Mehdi, S.J.; Morris, C.A.; Mashouri, L.; Yoon, D. Animal Models of Multiple Myeloma Bone Disease. Front. Genet. 2021, 12, 640954. [Google Scholar] [CrossRef] [PubMed]
- Rossi, M.; Botta, C.; Arbitrio, M.; Grembiale, R.D.; Tagliaferri, P.; Tassone, P. Mouse models of multiple myeloma: Technologic platforms and perspectives. Oncotarget 2018, 9, 20119–20133. [Google Scholar] [CrossRef] [Green Version]
- Pisano, M.; Cheng, Y.; Sun, F.; Dhakal, B.; D’Souza, A.; Chhabra, S.; Knight, J.M.; Rao, S.; Zhan, F.; Hari, P.; et al. Laboratory Mice—A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front. Immunol. 2021, 12, 667054. [Google Scholar] [CrossRef] [PubMed]
- Yaccoby, S.; Barlogie, B.; Epstein, J. Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations. Blood 1998, 92, 2908–2913. [Google Scholar] [CrossRef]
- Kyoizumi, S.; Baum, C.M.; Kaneshima, H.; McCune, J.M.; Yee, E.J.; Namikawa, R. Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood 1992, 79, 1704–1711. [Google Scholar] [CrossRef] [Green Version]
- Urashima, M.; Chen, B.P.; Chen, S.; Pinkus, G.S.; Bronson, R.T.; Dedera, D.A.; Hoshi, Y.; Teoh, G.; Ogata, A.; Treon, S.P.; et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997, 90, 754–765. [Google Scholar] [CrossRef]
- Yata, K.; Yaccoby, S. The SCID-rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004, 18, 1891–1897. [Google Scholar] [CrossRef] [Green Version]
- Das, R.; Strowig, T.; Verma, R.; Koduru, S.; Hafemann, A.; Hopf, S.; Kocoglu, M.H.; Borsotti, C.; Zhang, L.; Branagan, A.; et al. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat. Med. 2016, 22, 1351–1357. [Google Scholar] [CrossRef] [Green Version]
- Potter, M. Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol. Rev. 1972, 52, 631–719. [Google Scholar] [CrossRef]
- Eisen, H.N.; Simms, E.S.; Potter, M. Mouse myeloma proteins with antihapten antibody acitivity. The protein produced by plasma cell tumor MOPC-315. Biochemistry 1968, 7, 4126–4134. [Google Scholar] [CrossRef]
- Hofgaard, P.O.; Jodal, H.C.; Bommert, K.; Huard, B.; Caers, J.; Carlsen, H.; Schwarzer, R.; Schünemann, N.; Jundt, F.; Lindeberg, M.M.; et al. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS ONE 2012, 7, e51892. [Google Scholar] [CrossRef] [Green Version]
- Dahlhoff, J.; Manz, H.; Steinfatt, T.; Delgado-Tascon, J.; Seebacher, E.; Schneider, T.; Wilnit, A.; Mokhtari, Z.; Tabares, P.; Böckle, D.; et al. Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. Leukemia 2022, 36, 790–800. [Google Scholar] [CrossRef] [PubMed]
- Radl, J.; Hollander, C.F.; van den Berg, P.; de Glopper, E. Idiopathic paraproteinaemia. I. Studies in an animal model--the ageing C57BL/KaLwRij mouse. Clin. Exp. Immunol. 1978, 33, 395–402. [Google Scholar] [PubMed]
- Radl, J. Animal model of human disease. Benign monoclonal gammopathy (idiopathic paraproteinemia). Am. J. Pathol. 1981, 105, 91–93. [Google Scholar] [PubMed]
- Radl, J.; De Glopper, E.D.; Schuit, H.R.; Zurcher, C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J. Immunol. 1979, 122, 609–613. [Google Scholar] [CrossRef]
- Radl, J.; Croese, J.W.; Zurcher, C.; Van den Enden-Vieveen, M.H.; de Leeuw, A.M. Animal model of human disease. Multiple myeloma. Am. J. Pathol. 1988, 132, 593–597. [Google Scholar]
- Manning, L.S.; Berger, J.D.; O’Donoghue, H.L.; Sheridan, G.N.; Claringbold, P.G.; Turner, J.H. A model of multiple myeloma: Culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br. J. Cancer 1992, 66, 1088–1093. [Google Scholar] [CrossRef] [Green Version]
- Buckle, C.H.; De Leenheer, E.; Lawson, M.A.; Yong, K.; Rabin, N.; Perry, M.; Vanderkerken, K.; Croucher, P.I. Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma. PLoS ONE 2012, 7, e41127. [Google Scholar] [CrossRef] [Green Version]
- Asosingh, K.; Radl, J.; Van Riet, I.; Van Camp, B.; Vanderkerken, K. The 5TMM series: A useful in vivo mouse model of human multiple myeloma. Hematol. J. 2000, 1, 351–356. [Google Scholar] [CrossRef]
- Chesi, M.; Robbiani, D.F.; Sebag, M.; Chng, W.J.; Affer, M.; Tiedemann, R.; Valdez, R.; Palmer, S.E.; Haas, S.S.; Stewart, A.K.; et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13, 167–180. [Google Scholar] [CrossRef] [Green Version]
- Chesi, M.; Matthews, G.M.; Garbitt, V.M.; Palmer, S.E.; Shortt, J.; Lefebure, M.; Stewart, A.K.; Johnstone, R.W.; Bergsagel, P.L. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012, 120, 376–385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, K.; Chen, X. Positron emission tomography imaging of cancer biology: Current status and future prospects. Semin. Oncol. 2011, 38, 70–86. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Conti, M.; Eriksson, L. Physics of pure and non-pure positron emitters for PET: A review and a discussion. EJNMMI Phys. 2016, 3, 8. [Google Scholar] [CrossRef] [Green Version]
- Rong, J.; Haider, A.; Jeppesen, T.E.; Josephson, L.; Liang, S.H. Radiochemistry for positron emission tomography. Nat. Commun. 2023, 14, 3257. [Google Scholar] [CrossRef]
- Jamet, B.; Bailly, C.; Carlier, T.; Touzeau, C.; Nanni, C.; Zamagni, E.; Barré, L.; Michaud, A.V.; Chérel, M.; Moreau, P.; et al. Interest of Pet Imaging in Multiple Myeloma. Front. Med. 2019, 6, 69. [Google Scholar] [CrossRef] [Green Version]
- Seam, P.; Juweid, M.E.; Cheson, B.D. The role of FDG-PET scans in patients with lymphoma. Blood 2007, 110, 3507–3516. [Google Scholar] [CrossRef]
- Aljama, M.A.; Sidiqi, M.H.; Buadi, F.K.; Lacy, M.Q.; Gertz, M.A.; Dispenzieri, A.; Dingli, D.; Muchtar, E.; Fonder, A.L.; Hayman, S.R.; et al. Utility and prognostic value of (18) F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am. J. Hematol. 2018, 93, 1518–1523. [Google Scholar] [CrossRef] [Green Version]
- Grover, V.P.; Tognarelli, J.M.; Crossey, M.M.; Cox, I.J.; Taylor-Robinson, S.D.; McPhail, M.J. Magnetic Resonance Imaging: Principles and Techniques: Lessons for Clinicians. J. Clin. Exp. Hepatol. 2015, 5, 246–255. [Google Scholar] [CrossRef] [Green Version]
- Messiou, C.; Hillengass, J.; Delorme, S.; Lecouvet, F.E.; Moulopoulos, L.A.; Collins, D.J.; Blackledge, M.D.; Abildgaard, N.; Østergaard, B.; Schlemmer, H.P.; et al. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology 2019, 291, 5–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rama, S.; Suh, C.H.; Kim, K.W.; Durieux, J.C.; Ramaiya, N.H.; Tirumani, S.H. Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis. AJR. Am. J. Roentgenol. 2022, 218, 602–613. [Google Scholar] [CrossRef] [PubMed]
- Matteucci, F.; Paganelli, G.; Martinelli, G.; Cerchione, C. PET/CT in Multiple Myeloma: Beyond FDG. Front. Oncol. 2020, 10, 622501. [Google Scholar] [CrossRef]
- Lu, Y.Y.; Chen, J.H.; Lin, W.Y.; Liang, J.A.; Wang, H.Y.; Tsai, S.C.; Kao, C.H. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: A systematic review and meta-analysis. Clin. Nucl. Med. 2012, 37, 833–837. [Google Scholar] [CrossRef]
- Duncan, K.; Rosean, T.R.; Tompkins, V.S.; Olivier, A.; Sompallae, R.; Zhan, F.; Tricot, G.; Acevedo, M.R.; Ponto, L.L.; Walsh, S.A.; et al. (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J. 2013, 3, e165. [Google Scholar] [CrossRef]
- Rutsch, S.; Neppalli, V.T.; Shin, D.M.; DuBois, W.; Morse, H.C., 3rd; Goldschmidt, H.; Janz, S. IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood 2010, 115, 1746–1754. [Google Scholar] [CrossRef]
- Charalampous, C.; Goel, U.; Broski, S.M.; Dingli, D.; Kapoor, P.; Gertz, M.A.; Lacy, M.Q.; Dispenzieri, A.; Hayman, S.R.; Buadi, F.; et al. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Adv. 2022, 6, 2763–2772. [Google Scholar] [CrossRef] [PubMed]
- Mesguich, C.; Hulin, C.; Latrabe, V.; Lascaux, A.; Bordenave, L.; Hindié, E. 18F-FDG PET/CT and MRI in the Management of Multiple Myeloma: A Comparative Review. Front. Nucl. Med. 2022, 1, 808627. [Google Scholar] [CrossRef]
- Fonseca, R.; Arribas, M.; Wiedmeier-Nutor, J.E.; Kusne, Y.N.; González Vélez, M.; Kosiorek, H.E.; Butterfield, R.D.J.; Kirsch, I.R.; Mikhael, J.R.; Stewart, A.K.; et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023, 13, 32. [Google Scholar] [CrossRef]
- Hathi, D.; Chanswangphuwana, C.; Cho, N.; Fontana, F.; Maji, D.; Ritchey, J.; O’Neal, J.; Ghai, A.; Duncan, K.; Akers, W.J.; et al. Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. Sci. Rep. 2022, 12, 30. [Google Scholar] [CrossRef]
- Jiang, M.; Ferdani, R.; Shokeen, M.; Anderson, C.J. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors. Nucl. Med. Biol. 2013, 40, 245–251. [Google Scholar] [CrossRef] [Green Version]
- Ghai, A.; Fettig, N.; Fontana, F.; DiPersio, J.; Rettig, M.; Neal, J.O.; Achilefu, S.; Shoghi, K.I.; Shokeen, M. In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [(18)F]FDG and [(64)Cu]Cu-LLP2A PET. EJNMMI Res. 2021, 11, 97. [Google Scholar] [CrossRef] [PubMed]
- Soodgupta, D.; Hurchla, M.A.; Jiang, M.; Zheleznyak, A.; Weilbaecher, K.N.; Anderson, C.J.; Tomasson, M.H.; Shokeen, M. Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma. PLoS ONE 2013, 8, e55841. [Google Scholar] [CrossRef]
- Laforest, R.; Ghai, A.; Fraum, T.J.; Oyama, R.; Frye, J.; Kaemmerer, H.; Gaehle, G.; Voller, T.; Mpoy, C.; Rogers, B.E.; et al. First-in-Humans Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging. J. Nucl. Med. 2023, 64, 320–328. [Google Scholar] [CrossRef]
- Soodgupta, D.; Zhou, H.; Beaino, W.; Lu, L.; Rettig, M.; Snee, M.; Skeath, J.; DiPersio, J.F.; Akers, W.J.; Laforest, R.; et al. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. J. Nucl. Med. 2016, 57, 640–645. [Google Scholar] [CrossRef] [Green Version]
- Ullah, T.R. The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond. J. Bone Oncol. 2019, 17, 100253. [Google Scholar] [CrossRef]
- Lapa, C.; Schreder, M.; Schirbel, A.; Samnick, S.; Kortüm, K.M.; Herrmann, K.; Kropf, S.; Einsele, H.; Buck, A.K.; Wester, H.J.; et al. [(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma—Comparison to [(18)F]FDG and laboratory values. Theranostics 2017, 7, 205–212. [Google Scholar] [CrossRef] [PubMed]
- Pan, Q.; Cao, X.; Luo, Y.; Li, J.; Feng, J.; Li, F. Chemokine receptor-4 targeted PET/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: Comparison to (18)F-FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 537–546. [Google Scholar] [CrossRef] [PubMed]
- Saltarella, I.; Desantis, V.; Melaccio, A.; Solimando, A.G.; Lamanuzzi, A.; Ria, R.; Storlazzi, C.T.; Mariggiò, M.A.; Vacca, A.; Frassanito, M.A. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells 2020, 9, 167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yoon, J.K.; Park, B.N.; Ryu, E.K.; An, Y.S.; Lee, S.J. Current Perspectives on (89)Zr-PET Imaging. Int. J. Mol. Sci. 2020, 21, 4309. [Google Scholar] [CrossRef] [PubMed]
- Ghai, A.; Maji, D.; Cho, N.; Chanswangphuwana, C.; Rettig, M.; Shen, D.; DiPersio, J.; Akers, W.; Dehdashti, F.; Achilefu, S.; et al. Preclinical Development of CD38-Targeted [(89)Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. J. Nucl. Med. 2018, 59, 216–222. [Google Scholar] [CrossRef] [Green Version]
- Ulaner, G.A.; Sobol, N.B.; O’Donoghue, J.A.; Kirov, A.S.; Riedl, C.C.; Min, R.; Smith, E.; Carter, L.M.; Lyashchenko, S.K.; Lewis, J.S.; et al. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology 2020, 295, 606–615. [Google Scholar] [CrossRef]
- Caserta, E.; Chea, J.; Minnix, M.; Poku, E.K.; Viola, D.; Vonderfecht, S.; Yazaki, P.; Crow, D.; Khalife, J.; Sanchez, J.F.; et al. Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood 2018, 131, 741–745. [Google Scholar] [CrossRef]
- Krishnan, A.; Adhikarla, V.; Poku, E.K.; Palmer, J.; Chaudhry, A.; Biglang-Awa, V.E.; Bowles, N.; Nathwani, N.; Rosenzweig, M.; Sahebi, F.; et al. Identifying CD38+ cells in patients with multiple myeloma: First-in-human imaging using copper-64-labeled daratumumab. Blood Adv. 2020, 4, 5194–5202. [Google Scholar] [CrossRef] [PubMed]
- Herrero Alvarez, N.; Michel, A.L.; Viray, T.D.; Mayerhoefer, M.E.; Lewis, J.S. 89Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas. ACS Omega 2023, 8, 22486–22495. [Google Scholar] [CrossRef] [PubMed]
- Bailly, C.; Gouard, S.; Guérard, F.; Chalopin, B.; Carlier, T.; Faivre-Chauvet, A.; Remaud-Le Saëc, P.; Bourgeois, M.; Chouin, N.; Rbah-Vidal, L.; et al. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between (89)Zr- and (64)Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. Int. J. Mol. Sci. 2019, 20, 2564. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barnes, T.A.; Amir, E. HYPE or HOPE: The prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 2017, 117, 451–460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, Y.; Ma, C.; Zhang, Q.; Ye, J.; Wang, F.; Zhang, Y.; Hunborg, P.; Varvares, M.A.; Hoft, D.F.; Hsueh, E.C.; et al. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget 2015, 6, 17462–17478. [Google Scholar] [CrossRef] [Green Version]
- Zhang, D.; He, W.; Wu, C.; Tan, Y.; He, Y.; Xu, B.; Chen, L.; Li, Q.; Jiang, J. Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer. Front. Immunol. 2019, 10, 71. [Google Scholar] [CrossRef] [Green Version]
- Almangush, A.; Jouhi, L.; Atula, T.; Haglund, C.; Mäkitie, A.A.; Hagström, J.; Leivo, I. Tumour-infiltrating lymphocytes in oropharyngeal cancer: A validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group. Br. J. Cancer 2022, 126, 1589–1594. [Google Scholar] [CrossRef]
- Chen, L.; Han, X. Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future. J. Clin. Investig. 2015, 125, 3384–3391. [Google Scholar] [CrossRef] [Green Version]
- Das, S.; Johnson, D.B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 2019, 7, 306. [Google Scholar] [CrossRef] [PubMed]
- Kumagai, S.; Togashi, Y.; Kamada, T.; Sugiyama, E.; Nishinakamura, H.; Takeuchi, Y.; Vitaly, K.; Itahashi, K.; Maeda, Y.; Matsui, S.; et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 2020, 21, 1346–1358. [Google Scholar] [CrossRef]
- Kist de Ruijter, L.; van de Donk, P.P.; Hooiveld-Noeken, J.S.; Giesen, D.; Elias, S.G.; Lub-de Hooge, M.N.; Oosting, S.F.; Jalving, M.; Timens, W.; Brouwers, A.H.; et al. Whole-body CD8(+) T cell visualization before and during cancer immunotherapy: A phase 1/2 trial. Nat. Med. 2022, 28, 2601–2610. [Google Scholar] [CrossRef] [PubMed]
- Niemeijer, A.N.; Leung, D.; Huisman, M.C.; Bahce, I.; Hoekstra, O.S.; van Dongen, G.; Boellaard, R.; Du, S.; Hayes, W.; Smith, R.; et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat. Commun. 2018, 9, 4664. [Google Scholar] [CrossRef] [PubMed]
- Tamura, H.; Ishibashi, M.; Yamashita, T.; Tanosaki, S.; Okuyama, N.; Kondo, A.; Hyodo, H.; Shinya, E.; Takahashi, H.; Dong, H.; et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013, 27, 464–472. [Google Scholar] [CrossRef] [Green Version]
- Zelle-Rieser, C.; Thangavadivel, S.; Biedermann, R.; Brunner, A.; Stoitzner, P.; Willenbacher, E.; Greil, R.; Jöhrer, K. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J. Hematol. Oncol. 2016, 9, 116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bredella, M.A.; Steinbach, L.; Caputo, G.; Segall, G.; Hawkins, R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am. J. Roentgenol. 2005, 184, 1199–1204. [Google Scholar] [CrossRef]
- Tashima, H.; Yoshida, E.; Wakizaka, H.; Takahashi, M.; Nagatsu, K.; Tsuji, A.B.; Kamada, K.; Parodi, K.; Yamaya, T. 3D Compton image reconstruction method for whole gamma imaging. Phys. Med. Biol. 2020, 65, 225038. [Google Scholar] [CrossRef]
Radionuclide | Abbreviation | Emission Type | Half-Life | PET Radiotracers in Various Cancer Types |
---|---|---|---|---|
Carbon-11 | 11C | β+ | 20.4 min | 11C-choline, 11C-acetate, 11C-methionine |
Nitrogen-13 | 13N | β+ | 10.0 min | 13N-ammonia |
Oxygen-15 | 15O | β+ | 2.0 min | 15O-oxygen |
Fluorine-18 | 18F | β+ | 110 min | 18F-FDG, 18F-FET, 18F-fluorocholine, 18F-fluoride |
Copper-64 | 64Cu | β+ | 12.7 h | 64Cu-LLP2A, 64Cu-pembrolizumab, 64Cu-pentixafor, 64Cu-Rituximab, 64Cu-Bombesin, 64Cu-Trastuzumab |
Zirconium-89 | 89Zr | β+ | 78.4 h | 89Zr-Daratumumab, 89Zr-Trastuzumab, 89Zr-atezolizumab, 89Zr-bevacizumab, 89Zr-girentuximab |
Gallium-68 | 68Ga | β+/γ | 67.8 min | 68Ga-pentixafor, 68Ga-FAPI, 68Ga-PSMA, 68Ga-GRP |
Bromine-76 | 76Br | β+/γ | 16.2 h | |
Rubidium-82 | 82Rb | β+/γ | 1.3 min | |
Yttrium-86 | 86Y | β+/γ | 14.7 h | |
Iodine-124 | 124I | β+/γ | 100.2 h | 123I-Iodometomidate, 123I-MIBG |
Tracer Type | Radiotracer | Target/Mechanism | Phase | NCT Number |
---|---|---|---|---|
Unspecific Tracer | 18F-fluciclovine | Amino acid metabolism | Not Applicable | NCT03966443 |
18F-choline | Cell membrane synthesis | Phase 3 | NCT03891914 | |
11C-acetate | Fatty acid metabolism | Phase 2 | NCT03262389 | |
11C-methionine | Amino acid metabolism | |||
18F-fluorocholine | Lipid metabolism | Not Applicable | NCT04349358 | |
18F-fludarabine | Purine nucleoside analog | Phase 1 | NCT03832127 | |
Specific Tracer | 64Cu-LLP2A | VLA4-targeted ligand | Early phase 1 | NCT03804424 |
68Ga-pentixafor | CXCR4-targeted ligand | Early phase 1 Early phase 1 Early phase 1 Phase 2 | NCT03436342 NCT05364177 NCT05093335 NCT04561492 | |
68Ga-pentixather | CXCR4-targeted ligand | Early phase 1 | NCT05364177 | |
18F-PSMA-1007 | Prostate specific membrane antigen (PSMA)-targeted ligand | Not Applicable | NCT05448404 | |
18F-tetrafluoroborate (BF4) | Sodium/iodide symporter (NIS)-targeted ligand | phae1/2 | NCT02907073 | |
89Zr-daratumumab | Anti-CD38 antibody | Phae1/2 Phase2 Phase 2 | NCT03665155 NCT04467281 NCT04814615 | |
64Cu-daratumumab | Anti-CD38 antibody | Phase 1 | NCT03311828 | |
89Zr-satuximab | Anti-CD38 antibody | |||
68Ga-Nb1053 | CD38-specific single domain antibody (Nb1053) | |||
89Zr-elotuzumab | Anti-SLAMF7 antibody | |||
89Zr-bevacizumab | Anti-VEGF antibody | Not Applicable | NCT01859234 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ishibashi, M.; Takahashi, M.; Yamaya, T.; Imai, Y. Current and Future PET Imaging for Multiple Myeloma. Life 2023, 13, 1701. https://doi.org/10.3390/life13081701
Ishibashi M, Takahashi M, Yamaya T, Imai Y. Current and Future PET Imaging for Multiple Myeloma. Life. 2023; 13(8):1701. https://doi.org/10.3390/life13081701
Chicago/Turabian StyleIshibashi, Mariko, Miwako Takahashi, Taiga Yamaya, and Yoichi Imai. 2023. "Current and Future PET Imaging for Multiple Myeloma" Life 13, no. 8: 1701. https://doi.org/10.3390/life13081701